内皮SHMT2通过非经典通路驱动肺动脉高压肺血管重塑
该研究通过缺氧处理的人肺动脉内皮细胞蛋白组学发现SHMT2为肺动脉高压(PH)潜在靶点,并在患者肺组织及多种啮齿类PH模型中验证其表达上调。内皮细胞特异性敲除Shmt2减轻小鼠PH血管重塑与右心功能障碍,过表达则加重;机制上SHMT2通过非经典功能阻断RhoB的K63泛素化溶酶体降解,虚拟筛选获得的小分子Namodenoson在动物模型中显示预防和治疗PH的作用。
要点
- 内皮SHMT2在PH患者及多种啮齿类PH模型中表达上调。
- 内皮细胞特异性敲除Shmt2减轻小鼠PH血管重塑和右心功能障碍。
- SHMT2通过非经典功能阻断RhoB的K63泛素化溶酶体降解促内皮功能障碍。
核心结论
- 内皮SHMT2是PH发病的重要贡献因子,其非经典SHMT2-RhoB通路促进内皮功能障碍,靶向该通路可能成为PH潜在治疗策略。
研究设计与样本
- 研究评估了PH患者肺样本及啮齿类PH模型(缺氧暴露小鼠、野百合碱或Sugen 5416/缺氧诱导大鼠)中SHMT2的表达与功能。
- 通过条件性敲除和腺相关病毒9介导的基因调控实现内皮细胞特异性SHMT2功能缺失与获得。
- 体外研究在缺氧处理的人肺动脉内皮细胞和HEK-293T细胞中进行,并采用虚拟筛选鉴定靶向SHMT2非代谢功能的小分子抑制剂。
主要发现
- SHMT2主要在PH患者及多种啮齿类PH模型的肺血管内皮中上调。
- 体内内皮细胞特异性敲除Shmt2显著减轻PH小鼠的肺血管重塑和右心室功能障碍,而内皮细胞特异性过表达Shmt2加重PH发展。
- 腺相关病毒9介导的内皮Shmt2敲低减轻大鼠模型的PH表型。
- 机制上SHMT2主要通过非经典功能阻断RhoB的K63泛素化介导的溶酶体降解,促进缺氧诱导的内皮屏障功能障碍。
- 虚拟筛选鉴定Namodenoson为靶向SHMT2-RhoB通路的小分子抑制剂,体内显示预防和治疗PH的效果。
临床怎么用
- 内皮SHMT2-RhoB通路可作为PH潜在治疗靶点,Namodenoson在动物模型中显示预防和治疗效果,但尚未进入临床。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary hypertension (PH) is a progressive, life-threatening disease characterized primarily by pulmonary vascular remodeling in which endothelial dysfunction plays a vital role. However, the molecular factors contributing to this pathological process remain incompletely understood. Through proteomic analysis of hypoxia-treated human pulmonary artery endothelial cells, we identified serine hydroxymethyltransferase 2 (SHMT2) as a potential target in PH, but its role in disease pathogenesis and the underlying mechanisms remain unclear. METHODS: The expression and function of SHMT2 were assessed in lung samples from patients with PH and in rodent PH models, including hypoxia-exposed mice and monocrotaline- or Sugen 5416/hypoxia-induced rats. Endothelial cell-specific SHMT2 loss and gain of function were achieved by conditional knockout and adeno-associated virus 9-mediated gene modulation. In vitro studies were performed in hypoxia-treated human pulmonary artery endothelial cells and HEK-293T cells. Virtual screening was used to identify a small-molecule inhibitor targeting the nonmetabolic function of SHMT2, and its therapeutic potential was further evaluated in rodent PH models. RESULTS: SHMT2 was upregulated predominantly in pulmonary vascular endothelium of patients with PH and multiple rodent PH models. In vivo, endothelial cell-specific deletion of Shmt2 markedly attenuated pulmonary vascular remodeling and right ventricular dysfunction in PH mice, whereas endothelial cell-specific Shmt2 overexpression aggravated PH development. Consistently, adeno-associated virus 9-mediated endothelial Shmt2 knockdown alleviated PH phenotypes in rat models. Mechanistically, SHMT2 promoted hypoxia-induced endothelial barrier dysfunction mainly through a noncanonical function by blocking the K63-ubiquitin-mediated lysosomal degradation of ras homolog family member B (RhoB). Additional in vivo studies supported an important role of the endothelial SHMT2-RhoB axis in pulmonary vascular remodeling of PH. Through virtual screening, Namodenoson was identified as a small-molecule inhibitor targeting the SHMT2-RhoB pathway. In vivo, Namodenoson showed both preventive and therapeutic effects against PH. CONCLUSIONS: This study highlights endothelial SHMT2 as an important contributor to PH pathogenesis and reveals a noncanonical SHMT2-RhoB pathway that promotes endothelial dysfunction. Targeting this pathway may represent a potential therapeutic strategy for PH.
引用
- Wang Q, Tian J, Liu D, et al. Endothelial SHMT2 Drives Pulmonary Vascular Remodeling Through Noncanonical Pathway in Pulmonary Hypertension. Circulation. 2026. PMID: 42267432. doi:10.1161/CIRCULATIONAHA.125.066183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。